Adaptation of human and simian immunodeficiency viruses for resistance to tetherin/BST-2

Current HIV Research

Volumn 10, Issue 4, 2012, Pages 277-282

  Serra Moreno, Ruth ^a   Evans, David T ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CD317; Env; HIV; HM1.24; Innate immunity; Interferon; Monkey; Nef; Primate; Restriction factor; SIV; Vpu

Indexed keywords

GLYCOPROTEIN GP 41; MEMBRANE PROTEIN; NEF PROTEIN; TETHERIN; UNCLASSIFIED DRUG; VPU PROTEIN;

ADAPTATION; ARTICLE; CD4+ T LYMPHOCYTE; CYTOPLASM; GENE DELETION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MACACA; NONHUMAN; PROTEIN DOMAIN; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS RESISTANCE;

ADAPTATION, BIOLOGICAL; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GPI-LINKED PROTEINS; HIV-1; HIV-2; HOST-PATHOGEN INTERACTIONS; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; INTERFERONS; MACACA MULATTA; MOLECULAR SEQUENCE DATA; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PAN TROGLODYTES; PHYLOGENY; SIMIAN IMMUNODEFICIENCY VIRUS; SPECIES SPECIFICITY; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EID: 84862615532     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212800792496     Document Type: Article

References (66)

1. Varthakavi V, Smith RM, Bour SP, Strebel K, Spearman P. Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc Natl Acad Sci U S A 2003; 100: 15154-9.
2. Neil SJ, Eastman SW, Jouvenet N, Bieniasz PD. HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog 2006; 2(5): e39.
3. Neil SJ, Sandrin V, Sundquist WI, Bieniasz PD. An interferonalpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2007; 2(3): 193-203.
4. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451(7177): 425-30.
5. Van Damme N, Goff D, Katsura C, et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008; 3(4): 245-52.
6. Jouvenet N, Neil SJ, Zhadina M, et al. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol 2009; 83(4): 1837-44.
7. Mansouri M, Viswanathan K, Douglas JL, et al. Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus. J Virol 2009; 83(19): 9672-81.
8. Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J. Inhibition of Lassa and Marburg virus production by tetherin. J Virol 2009; 83(5): 2382-5.
9. Weidner JM, Jiang D, Pan XB, Chang J, Block TM, Guo JT. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol 2010; 84(24): 12646-57.
10. Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, Banting G. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 2003; 4: 694-709.
11. Perez-Caballero D, Zang T, Ebrahimi A, et al. Tetherin Inhibits HIV-1 Release by Directly Tethering Virions to Cells. Cell 2009; 139(3): 499-511.
12. Rollason R, Korolchuk V, Hamilton C, Schu P, Banting G. Clatharin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. J Cell Sci 2007; 120: 3850-058.
13. Andrew AJ, Miyagi E, Kao S, Strebel K. The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology 2009; 6(1): 80.
14. Lehmann M, Rocha S, Mangeat B, et al. Quantitative Multicolor Super-Resolution Microscopy Reveals Tetherin HIV-1 Interaction. PLoS Pathog 2011; 7(12): e1002456.
15. Iwabu Y, Fujita H, Kinomoto M, et al. HIV-1 accessory protein Vpu internalizescell-surfaceBST-2/tetherinthrough transmembrane interactions leading to lysosomes. J Biol Chem 2009; 284(50): 35060-72.
16. Jia B, Serra-Moreno R, Neidermyer W, et al. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 2009; 5(5): e1000429.
17. Zhang F, Wilson SJ, Landford WC, et al. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 2009; 6(1): 54-67.
18. Sauter D, Schindler M, Specht A, et al. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 2009; 6(5): 409-21.
19. Sauter D, Vogl M, Kirchhoff F. Ancient origin of a deletion in human BST2/Tetherin that confers protection against viral zoonoses. Human mutation 2011; 32(11): 1243-5.
20. Zhang F, Landford WN, Ng M, McNatt MW, Bieniasz PD, Hatziioannou T. SIV Nef proteins recruit the AP-2 complex to antagonize Tetherin and facilitate virion release. PLoS Pathog; 7(5): e1002039.
21. Sauter D, Specht A, Kirchhoff F. Tetherin: holding on and letting go. Cell 2010; 141(3): 392-8.
22. Cohen EA, Terwilliger EF, Sodroski JG, Haseltine WA. Identification of a protein encoded by the vpu gene of HIV-1. Nature 1988; 334(6182): 532-4.
23. Huet T, Cheynier R, Meyerhans A, Roelants G, Wain-Hobson S. Genetic organization of a chimpanzee lentivirus related to HIV-1. Nature 1990; 345(6273): 356-9.
24. Gao F, Bailes E, Robertson DL, et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999; 397(6718): 436-41.
25. Santiago ML, Bibollet-Ruche F, Bailes E, et al. Amplification of a complete simian immunodeficiency virus genome from fecal RNA of a wild chimpanzee. J Virol 2003; 77(3): 2233-42.
26. Barlow KL, Ajao AO, Clewley JP. Characterization of a novel simian immunodeficiency virus (SIVmonNG1) genome sequence from a mona monkey (Cercopithecus mona). J Virol 2003; 77(12): 6879-88.
27. Courgnaud V, Abela B, Pourrut X, et al. Identification of a new simian immunodeficiency virus lineage with a vpu gene present among different cercopithecus monkeys (C. mona, C. cephus, and C. nictitans) from Cameroon. J Virol 2003; 77(23): 12523-34.
28. Courgnaud V, Salemi M, Pourrut X, et al. Characterization of a novel simian immunodeficiency virus with a vpu gene from greater spot-nosed monkeys (Cercopithecus nictitans) provides new insights into simian/human immunodeficiency virus phylogeny. J Virol 2002; 76(16): 8298-309.
29. Dazza MC, Ekwalanga M, Nende M, et al. Characterization of a novel vpu-harboring simian immunodeficiency virus from a Dent's Mona monkey (Cercopithecus mona denti). J Virol 2005; 79(13): 8560-71.
30. Yang SJ, Lopez LA, Hauser H, Exline CM, Haworth KG, Cannon PM. Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology 2010; 7: 13.
31. Vigan R, Neil SJ. Separable Determinants of Subcellular Localization and Interaction Account for the Inability of Group O HIV-1 Vpu To Counteract Tetherin. J Virol 2011; 85(19): 9737-48.
32. Petit SJ, Blondeau C, Towers GJ. Analysis of the HIV-1 M group Vpu domains involved in antagonizing tetherin (BST-2). J Genl Virol 2011; 92(Pt 12): 2937-48.
33. Yang SJ, Lopez LA, Exline CM, Haworth KG, Cannon PM. Lack of adaptation to human tetherin in HIV-1 Group O and P. Retrovirology 2011;8: 78.
34. Lv M, Wang J, Wang X, et al. Polarity Changes in the Transmembrane Domain Core of HIV-1 Vpu Inhibits Its Anti- Tetherin Activity. PLoS One 6(6):e20890.
35. Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST- 2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog 2009; 5(9): e1000574.
36. Skasko M, Wang Y, Tian Y, et al. HIV-1 Vpu Protein Antagonizes Innate Restriction Factor BST-2 via Lipid-embedded Helix-Helix Interactions. J Biol Chem 2012; 287(1): 58-67.
37. Margottin F, Bour SP, Durand H, et al. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1998; 1(4): 565-74.
38. Mitchell RS, Katsura C, Skasko MA, et al. Vpu antagonizes BST- 2-mediated restriction of HIV-1 release via beta-TrCP and endolysosomal trafficking. PLoS Pathog 2009; 5(5): e1000450.
39. Douglas JL, Viswanathan K, McCarroll MN, Gustin JK, Fruh K, Moses AV. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. J Virol 2009; 83(16): 7931-47.
40. Tokarev AA, Munguia J, Guatelli JC. Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu. J Virol 2011; 85(1): 51-63.
41. Janvier K, Pelchen-Matthews A, Renaud J-B, Caillet M, Marsh M, Berlioz-Torrent C. The ESCRT-0 component HRS is required for HIV-1 vpu-mediated BST-2/tetherin down-regulation. PLoS Pathog 2011; 7: e1001265.
42. Lau D, Kwan W, Guatelli J. Role of the Endocytic Pathway in the Counteraction of BST-2 by Human Lentiviral Pathogens. J Virol 2011; 85(19): 9834-46.
43. Schmidt S, Fritz JV, Bitzegeio J, Fackler OT, Keppler OT. HIV-1 vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction. MBio 2011; 2: e00036-11.
44. Dube M, Roy BB, Guiot-Guillain P, et al. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog 2010; 6: e1000856.
45. Tervo H-M, Homann S, Ambiel I, Fritz JV, Fackler OT, Keppler OT.-TrCP is dispensable for Vpu's ability to overcome the CD317/tetherin-imposedrestrictiontoHIV-1 release. Retrovirology 2011; 8: 9.
46. Hauser H, Lopez LA, Yang SJ, et al. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology 2011; 8: 85.
47. McNatt MW, Zang T, Hatziioannou T, et al. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog 2009; 5(2): e1000300.
48. Gao F, Yue L, White AT, et al. Human infection by genetically diverse SIVsm-related HIV-2 in West Africa. Nature 1992; 358: 495-9.
49. Hahn BH, Shaw GM, Cock KMD, Sharp PM. AIDS as a Zoonosis: Scientific and public health implications. Science 2000; 287: 607-14.
50. de Silva TI, Cotten M, Rowland-Jones SL. HIV-2: the forgotten AIDS virus. Trends Microbiol 2008; 16(12): 588-95.
51. Bour S, Schubert U, Peden K, Strebel K. The envelope glycoprotein of human immunodeficiency viru type 2 enhances viral particle release: a vpu-like factor? J Virol 1996; 70: 820-9.
52. Bour S, Strebel K. The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J Virol 1996; 70(12): 8285-300.
53. LeTortorec A, Neil SJD. Antagonism and intracellular sequestration of human tetherin by the HIV-2 envelope glycoprotein. J Virol 2009; 83: 11966-78.
54. Gupta RK, Mlcochova P, Pelchen-Matthews A, et al. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST2/CD317 by intracellular sequestration. Proc Natl Acad Sci U S A 2009; 106: 20889-94.
55. Lopez LA, Yang SJ, Hauser H, et al. Ebola glycoprotein counteracts BST-2/tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J Virol 2010; 84: 7243-55.
56. Abada P, Noble B, Cannon PM. Functional domains within the human immunodeficiency virus type 2 envelope glycoprotein required to enhance virus production. J Virol 2005; 79: 3627-38.
57. Bour S, Akari H, Miyagi E, Strebel K. Naturally occurring amino acid substitutions in the HIV-2 ROD envelope glycoprotein regulate its ability to augment viral particle release. Virology 2003; 309: 85-98.
58. Johnson RP, Glickman RL, Yang JQ, et al. Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J Virol 1997; 71(10): 7711-8.
59. Almond N, Kent K, Cranage M, Rud E, Clarke B, Stott EJ. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 1995; 345(8961): 1342-4.
60. Connor RI, Montefiori DC, Binley JM, et al. Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Virol 1998; 72: 7501-9.
61. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992; 258(5090): 1938-41.
62. Alexander L, Illyinskii PO, Lang SM, et al. Determinants of increased replicative capacity of serially passaged simian immunodeficiency virus with nef deleted in rhesus monkeys. J Virol 2003; 77: 6823-35.
63. Serra-Moreno R, Jia B, Breed M, Alvarez X, Evans DT. compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic Nef-deleted SIV. Cell Host Microbe 2011; 9(1): 46-57.
64. Noble B, Abada P, Nunez-Iglesias J, Cannon PM. Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release. J Virol 2006; 80(6): 2924-32.
65. Lim ES, Malik HS, Emerman M. Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses. J Virol 2010; 84(14): 7124-34.
66. Evans DT, Serra-Moreno R, Singh RK, Guatelli JC. BST- 2/tetherin: a new component of the innate immune response to enveloped viruses. Trends Microbiol 2010; 18(9): 388-96.